Genetics: From Genes to Genomes, 5th edition
5th Edition
ISBN: 9780073525310
Author: Leland H. Hartwell, Michael L. Goldberg, Janice A. Fischer, Leroy Hood, Charles F. Aquadro
Publisher: McGraw-Hill Education
expand_more
expand_more
format_list_bulleted
Concept explainers
Videos
Question
Chapter 19, Problem 7P
Summary Introduction
a.
To describe:
The genesis of B cell lymphomas based on the given information.
Introduction:
The human immune system is a wonder of specificity and diversity. It consists of around a trillion B lymphocytes, specialized white blood cells. These cells can generate more than one billion different varieties of antibodies.
Summary Introduction
b.
To determine:
The method by which the nature of B cell lymphomas provides support for the clonal theory of cancer.
Introduction:
Cancer is a group of diseases that are characterized by abnormal cell proliferation with the ability to spread in different parts of the body.
Expert Solution & Answer
Want to see the full answer?
Check out a sample textbook solution
Students have asked these similar questions
Human cells are highly resistant to transformation. Experiments have shown that 5 regulatory circuits (pathways) have to be altered before human cells can grow as tumor cells in immunocompromised mice.
State each of these circuits. Explain how the alteration of the protein of that particular circuit leads to uncontrolled growth.
One of the ways that we know what the RB protein does in cells is that its inactivation is a common priority of tumor-initiating viruses. What advantage would a virus gain by inactivating RB function in its host cell?
Mutations in the RB gene are often associated with cancer. Explain how a mutation that results in a nonfunctional RB protein contributes to cancer.
Chapter 19 Solutions
Genetics: From Genes to Genomes, 5th edition
Ch. 19 - For each of the terms in the left column, choose...Ch. 19 - Characterize the differences between tumor cells...Ch. 19 - Prob. 3PCh. 19 - Prob. 4PCh. 19 - A carcinogenic compound is placed on the skin of...Ch. 19 - Prob. 6PCh. 19 - Prob. 7PCh. 19 - Molecules outside and inside the cell regulate the...Ch. 19 - Put the following steps in the correct ordered...Ch. 19 - a. Would you expect a cell to continue or to stop...
Ch. 19 - Prob. 11PCh. 19 - One of the hallmarks of mitotic anaphase is the...Ch. 19 - Concerning the Tools of Genetics Box Analysis of...Ch. 19 - Are genome and karyotype instabilities...Ch. 19 - Prob. 15PCh. 19 - A female patient 19 years old, whose symptoms are...Ch. 19 - Prob. 17PCh. 19 - Prob. 18PCh. 19 - Neurofibromatosis type 1 NF1; also known as von...Ch. 19 - Hepatocellular carcinoma is the most frequent form...Ch. 19 - Prob. 21PCh. 19 - Prob. 22PCh. 19 - Prob. 23P
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.Similar questions
- Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Should the physicians at UCLA have told Mr. Moore that his cells and its products were being commercially developed?arrow_forwardThe Adaptive Immune Response Is a Specific Defense Against Infection In cystic fibrosis gene therapy, scientists propose the use of viral vectors to deliver normal genes to cells in the lungs. What immunological risks are involved in this procedure?arrow_forwardWho Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Do you think that donors or patients who provide cells and/or tissues should retain ownership of their body parts or should share in any financial benefits that might derive from their use in research or commercial applications?arrow_forward
- Monoclonal antibodies are produced by immunizing a mouse with a particular antigen, then removing its spleen. Individual B cells producing mouse antibodies specific for the antigen are isolated from the spleen, then fused with cancer cells. Each of the resulting hybrid cells can be cloned, which means it can be cultured indefinitely in the laboratory. The resulting cell lines produce and secrete antibodies that recognize the antigen to which the mouse was immunized. These antibodies are called monoclonal antibodies. Some monoclonal antibodies are used for passive immunization. They are effective, but only in the immediate term. Antibodies that are produced by one’s own immune system can last up to about six months in the bloodstream, but those delivered in passive immunization often last for less than a week. Why the difference?arrow_forwardMice and humans with inactivating mutations in the gene encoding activation-induced cytidine deaminase (AID) have an immunodeficiency disease known as 'hyper IgM type 2'. Since AID is the enzyme that catalyzes the conversion of cytosines in the DNA to uracils, thereby initiating the process of somatic hypermutation, why do individuals with this deficiency only produce IgM antibodies?arrow_forwardOver time, cancer cells are known to produce weakly antigenic variants of cell surface proteins. This will result in ----. protection of cells from the immune system increase in cancer cell death by the immune system Neither A nor B. It will make no difference. Therapeutic antibodies used in the treatment of cancer are targeted at proteins located On the cell surface of cancer cells. On the cell surface of normal cells. In the nucleus of cancer cells. In the cytoplasm of cancer cells. C and D.arrow_forward
- When a mixture of different IgG antibody proteins are treated with the enzyme papain, each antibody is cleaved into three roughly equal size fragments. From each original antibody, two of the three fragments are identical to each other, and represent the ‘arms’ of the antibody ‘Y’. These fragments are known as Fab fragments. The third fragment is known as the Fc region, because this fragment will crystallize when purified. The reason a mixture of Fc fragments will crystallize is because: It is the only part of the antibody protein that can easily be purified at the high concentrations needed for crystallization. It has no disulfide bonds holding the domains together, as disulfide bonds will inhibit crystallization. It is the only fragment of the antibody that still has disulfide bonds, so it remains intact during the crystallization process. The Fc fragments of IgG are much more water soluble than the Fab fragments. All Fc fragments generated from a mixture of IgG molecules have the…arrow_forwardA wild-type mouse that is heterozygous for two immunoglobulin heavy chain alleles (IgHa/b) generates the population of B cells shown on the left of the figure below. A mouse strain, also IgHa/b, carries an inactivating mutation in the VpreB gene. In addition to producing fewer mature B cells than the wild-type mice, the VpreB-deficient mice generate B cells as shown on the right. What is the explanation of the difference seen between the wild-type and the VpreB-mutant B cells?arrow_forward4:17 Regarding chronic disease prevention, match each term with the phrase that best describes it Molecule produced by innate immune cells. that is involved in maintaining chronic inflammation A protein produced by the liver that is al frequently used marker of chronic inflammation The degree to which a certain food elevates blood glucose after it's eaten A small molecule that can bind to histones and DNA, frequently with the result of gene silencing An enzyme that rebuilds the end caps of chromosomes after each cell division, thus prolonging the life of the cell [Choose] [Choose] Interleukin-6 TNF-alpha Methyl Tag Glycemic Load C Reactive Protein Glycemic Index Telomerase [Choose] [Choose ] [Choose] Xarrow_forward
- Entanercept is a pharmaceutical that is composed of a recombinant receptor for human tumor necrosis factor, fused to the Fc portion of the immunoglobulin IgG. How does it work?arrow_forwardCan you please help me by drawing a serie of schematic figures that demonstrates the information in the paragraph below. The carboxy terminus of the p53 protein acts as an allosteric regulator of sequence-specific DNA binding. This was demonstrated initially by Hupp et al. (1992) using a bacterially expressed protein. Recombinant bacterial p53 bound poorly to DNA, and binding could be enhanced by the addition of antibodies specific to the C-terminal region of the protein. Phosphorylation of Ser315 and Ser392 within this domain also enhance sequence-specific DNA binding. Dephosphorylation of Ser376 of p53 after IR allows the association of 14-3-3 proteins with the C terminus of the protein (Waterman et al., 1998). Stavridi et al. (2001) demonstrate that this interaction is required for p53 to activate the downstream gene, p21waf1/cip1, and for the G1 cell cycle checkpoint arrest response. Interestingly, this dephosphorylation event seems to be ATM-dependent, possibly by a phosphatase…arrow_forwardAlthough mutations have been observed in many different genes, they have not been isolated in histones. Why does this seem reasonable? If one wanted to produce antibodies to histones, would it be an easy task? Explain your answer.arrow_forward
arrow_back_ios
SEE MORE QUESTIONS
arrow_forward_ios
Recommended textbooks for you
Human Heredity: Principles and Issues (MindTap Co...BiologyISBN:9781305251052Author:Michael CummingsPublisher:Cengage Learning
Human Heredity: Principles and Issues (MindTap Co...
Biology
ISBN:9781305251052
Author:Michael Cummings
Publisher:Cengage Learning
Immune System and Immune Response Animation; Author: Medical Sciences Animations;https://www.youtube.com/watch?v=JDdbUBXPKc4;License: Standard YouTube License, CC-BY
Immune response: summary; Author: Dr Bhavsar Biology;https://www.youtube.com/watch?v=ADANgHkX4OY;License: Standard Youtube License